ICPT
Income statement / Annual
Last year (2022), Intercept Pharmaceuticals, Inc.'s total revenue was $285.71 M,
a decrease of 21.39% from the previous year.
In 2022, Intercept Pharmaceuticals, Inc.'s net income was $115.17 M.
See Intercept Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
| Operating Revenue |
$285.71 M |
$363.47 M |
$312.69 M |
$252.00 M |
$179.80 M |
$130.96 M |
$24.95 M |
$2.78 M |
$1.74 M |
$1.62 M |
| Cost of Revenue |
$984,000.00
|
$3.10 M
|
$5.32 M
|
$4.21 M
|
$2.52 M
|
$1.37 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$284.73 M
|
$360.37 M
|
$307.37 M
|
$247.79 M
|
$177.29 M
|
$129.59 M
|
$24.95 M
|
$2.78 M
|
$1.74 M
|
$1.62 M
|
| Gross Profit Ratio |
1
|
0.99
|
0.98
|
0.98
|
0.99
|
0.99
|
1
|
1
|
1
|
1
|
| Research and Development Expenses |
$176.64 M
|
$185.27 M
|
$191.49 M
|
$242.80 M
|
$207.30 M
|
$191.50 M
|
$153.89 M
|
$128.19 M
|
$80.31 M
|
$27.94 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$255.47 M
|
$0.00
|
$0.00
|
$103.75 M
|
$34.60 M
|
$13.13 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$161.00
|
| Selling, General & Administrative Expenses |
$176.30 M
|
$230.86 M
|
$332.49 M
|
$317.42 M
|
$255.47 M
|
$273.70 M
|
$273.60 M
|
$103.75 M
|
$34.60 M
|
$13.13 M
|
| Other Expenses |
$6.52 M
|
$2.16 M
|
$4.41 M
|
$8.89 M
|
$6.77 M
|
$4.52 M
|
$3.90 M
|
$2.73 M
|
$776,000.00
|
$100,375.00
|
| Operating Expenses |
$352.94 M
|
$416.13 M
|
$523.98 M
|
$560.22 M
|
$462.78 M
|
$465.20 M
|
$427.49 M
|
$231.94 M
|
$114.91 M
|
$41.07 M
|
| Cost And Expenses |
$353.93 M
|
$419.23 M
|
$529.30 M
|
$564.43 M
|
$465.29 M
|
$466.57 M
|
$427.49 M
|
$231.94 M
|
$114.91 M
|
$41.07 M
|
| Interest Income |
$15.51 M
|
$47.77 M
|
$39.80 M
|
$33.35 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$21.39 M
|
$54.42 M
|
$48.05 M
|
$41.14 M
|
$30.52 M
|
$29.27 M
|
$14.20 M
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$6.52 M
|
$2.16 M
|
$4.41 M
|
$8.89 M
|
$4.58 M
|
$4.60 M
|
$3.83 M
|
$1.69 M
|
$442,797.00
|
$105,683.00
|
| EBITDA |
-$61.70 M |
-$53.60 M |
-$212.20 M |
-$303.54 M |
-$278.72 M |
-$331.10 M |
-$398.63 M |
-$226.43 M |
$57.66 M |
-$10.90 M |
| EBITDA Ratio |
-0.22
|
-0.15
|
-0.68
|
-1.2
|
-1.55
|
-2.53
|
-15.98
|
-81.39
|
33.1
|
-6.72
|
| Operating Income Ratio |
-0.24
|
-0.15
|
-0.69
|
-1.24
|
-1.59
|
-2.56
|
-16.13
|
-82.37
|
-64.97
|
-24.33
|
| Total Other Income/Expenses Net |
-$106.64 M
|
-$35.67 M
|
-$43.64 M
|
-$32.25 M
|
-$23.75 M
|
-$24.76 M
|
-$10.29 M
|
$2.73 M
|
-$170.06 M
|
-$28.34 M
|
| Income Before Tax |
-$174.86 M
|
-$91.43 M
|
-$274.88 M
|
-$344.68 M
|
-$309.24 M
|
-$360.37 M
|
-$412.83 M
|
-$226.43 M
|
-$283.23 M
|
-$67.79 M
|
| Income Before Tax Ratio |
-0.61
|
-0.25
|
-0.88
|
-1.37
|
-1.72
|
-2.75
|
-16.55
|
-81.39
|
-162.59
|
-41.81
|
| Income Tax Expense |
-$290.03 M
|
$53.60 M
|
$49.35 M
|
$46.37 M
|
$6.77 M
|
$29.19 M
|
$14.27 M
|
$1.04 M
|
$170.39 M
|
$28.44 M
|
| Net Income |
$115.17 M
|
-$145.02 M
|
-$324.23 M
|
-$391.05 M
|
-$309.24 M
|
-$360.37 M
|
-$412.83 M
|
-$226.43 M
|
-$283.23 M
|
-$67.79 M
|
| Net Income Ratio |
0.4
|
-0.4
|
-1.04
|
-1.55
|
-1.72
|
-2.75
|
-16.55
|
-81.39
|
-162.59
|
-41.81
|
| EPS |
3.41 |
-4.55 |
-9.83 |
-12.35 |
-10.86 |
-14.38 |
-16.74 |
-9.56 |
-13.63 |
-3.76 |
| EPS Diluted |
3.4 |
-4.55 |
-9.83 |
-12.35 |
-10.86 |
-14.38 |
-16.74 |
-9.56 |
-13.63 |
-3.76 |
| Weighted Average Shares Out |
$33.82 M
|
$31.86 M
|
$32.97 M
|
$31.65 M
|
$28.46 M
|
$25.05 M
|
$24.66 M
|
$23.69 M
|
$20.78 M
|
$18.03 M
|
| Weighted Average Shares Out Diluted |
$33.84 M
|
$31.89 M
|
$32.97 M
|
$31.65 M
|
$28.46 M
|
$25.05 M
|
$24.66 M
|
$23.69 M
|
$20.78 M
|
$18.03 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
